Skip to main content
. 2021 May 17;16(5):e0251863. doi: 10.1371/journal.pone.0251863

Table 2. Characteristics of included studies.

Study Country Design Patients Exercise HRV measures Other outcomes*
n analyzed Age, mean (years±SD) Men (%) Type / group Duration (months) Intensity Session /week Super-vision HRV parameters* Deep breathing ECG (min)
Abdelbasset 2019 Egypt RCT 20 52.4±4.6 100% HIIT 4 4 intervals of 4 min at 80–90% of MHR with 2 min at 50–60% of MHR between each 30 min 3 Yes HRV lying (RR↘, SDNN ↗, RMSSD↗, LF, HF↗, LF/HF↘) No 5 HbA1c, BMI, total cholesterol, HDL, LDL, triglycerides, VO2
20 51.5±5.1 Control -
Bellavere 2018 Italy R Comp. Type of exercise 19 57.1±1.6 68% End. 4 Up to 60–65% of HRR 60 min 3 Yes HRV lying and standing (TP, LF↘, HF↗, LF/HF↘) No 10 HbA1c, BMI, total cholesterol, HDL, LDL, triglycerides, VO2
11 53.4±2.0 82% Resist. Up to 3 sets of 10 repetitions at 70–80% 1-RM Yes
Bhagyalakshmi 2007 India Non-RCT 28 61.8±3.1 79% End. 9 Unclear 45 min 7 Yes HRV lying (↗ difference shortest and longest RR) Yes 1 HbA1c
20 59.5±2.8 50% Control -
Cassidy 2019 UK RCT 11 60.0±3.0 82% HIIT 3 5 intervals of 2 min (up to 3 min 50 s) at > 80 RPM and RPE 16–17 with 3 min recovery between each 30–40 min 3 No HRV lying (RR, SDNN, LF, HF, LF/HF) No 20 HbA1c, BMI, blood pressure, VO2
11 59.0±3.0 73% Control -
Duennwald 2014 Austria R Comp. Type of exercise 8 59.6±5.7 75% HIIT 1 5 intervals of 4 min at 90–95% of MHR with 3 min at 70% of MHR between each 70% of MHR 42 min 3 Yes HRV lying (RR, SDNN) No 4 HbA1c, BMI, blood pressure, total cholesterol, HDL, VO2
7 59.6±6.1 71% End. 50.3 min Yes
Faulkner 2014 USA Non-R T2DM vs no T2DM 9 14.7±1.8 11% End. (T2DM) 4 60–75% of MHR 60 min 5 No HRV 24h (RMSSD, pNN50, SDNN, TP, LF, HF) No 1440 HbA1c, BMI, total cholesterol, HDL, LDL, triglycerides, VO2
10 14.6±1.6 40% End. (No T2DM) No
Figueroa 2007 USA Non-R T2DM vs no T2DM 8 50.0±2.8 0% End. (T2DM) 4 65% of VO2peak 30–45 min 4 +/- HRV lying (LF, HF, LF/HF) Yes 5 HbA1c, BMI, blood pressure, VO2
12 48.0±6.9 0% End. (No T2DM) +/-
Goit 2014 Nepal Pre-post 20 42.2±6.4 100% End. 6 60–85% of HRR 50 min 3 Yes HRV lying (SDNN, RMSSD↗, pNN50↗, LF↘, HF↗, LF/HF↘) No 5 HbA1c, BMI, blood pressure, HDL, LDL, triglycerides
Goit 2017 Nepal Pre-post 41 44.2±4.5 100% End. 6 50–70% of HRR 50 min 3 Yes HRV lying (SDNN↗, RMSSD↗, pNN50↗, LF↘, HF↗, LF/HF↗) No 5 HbA1c, BMI, blood pressure, total cholesterol, HDL, LDL, triglycerides
Goulopoulou 2010 USA Non-R T2DM vs no T2DM 26 50.0±5.1 50% End. (T2DM) 4 65% of VO2peak 30–45 min 4 +/- HRV lying (TP) Yes 5 HbA1c, BMI, blood pressure, total cholesterol, HDL, LDL, triglycerides, VO2
36 49.0±6.0 39% End. (No T2DM) +/-
Kanaley 2009 USA Non-R. T2DM vs no T2DM 22 50.0±1.6 45% End. (T2DM) 4 65% of VO2peak 30–45 min 4 +/- HRV lying (TP) Yes 5 HbA1c, BMI, VO2
34 49.0±0.9 38% End. (No T2DM)
Kang 2016 Korea RCT 8 56.0±7.4 0% End. & Resist. 3 60% of HRR + 2 sets 9 exercises 8–12 repetitions at 1-RM of 60–80% 30 + 30 min 3 Yes HRV lying (RMSSD, SDNN, LF, HF, LF/HF) No 5 HbA1c, BMI, blood pressure, total cholesterol, HDL, LDL, triglycerides, VO2
8 57.5±4.6 0% Control -
Loimaala 2003 Finland RCT 24 53.6±6.2 100% End. & Resist. 12 65–75% of VO2peak 3 sets of 10–12 repetitions at 70–80% max. voluntary contraction 30 min 4 +/- HRV lying (SDNN, pNN50, LF, HF, LF/HF) No 1440 HbA1c, BMI, blood pressure, VO2
25 54.0±5.0 Control -
Moawd 2015 Egypt Non-R Comp. Type of exercise 20 50.5±8.6 100% End. 3 60–85% of HRR RPE “very to fairly light” up to “somewhat hard” 50 min 3 Yes HRV lying (RMSSD↗, SDNN↗, pNN50↗) No 10 BMI, blood pressure
18 51.3±6.1 100% Resist. 5–20 min -
Pagkalos 2008 Greece Non-R Comp. CAN status 15 55.8±5.6 27% End. (CAN -) 6 70–85% of HRR 45–75 min 3 Yes HRV lying (RMSSD↗, SDNN↗, pNN50↗, LF↘, HF↗, LF/HF↘) No 1440 HbA1c, BMI, blood pressure, total cholesterol, HDL, LDL, triglycerides, VO2
17 56.2±5.8 35% End. (CAN +) Yes
Parpa 2009 USA Pre-post 14 57.0±6.7 36% HIIT 3 6 intervals of 2 min at 80–90% of MHR with 2 min at 50–60% MHR between each 30 min 4 Yes HRV lying (SDNN↗) No 5 Blood pressure
Sacre 2014 Australia Non-RCT 22 59.0±10.0 59% End. & Resist. 6 RPE “moderate-vigorous” 75 min 2 +/- HRV lying (RR↘, SDNN↗, RMSSD, TP↗, LF, HF, LF/HF) No 5 HbA1c, BMI, blood pressure, total cholesterol, HDL, LDL, triglycerides
25 60.0±9.0 40% Control
Simmonds 2012 Australia R Comp. frequency & duration of sessions 8 68.6±2.8 0% End. 3 At 100% of Tge 60 min 2 unclear HRV lying (RR, SDNN↗, RMSSD↗, LF, HF↗, LF/HF) No 10 HbA1c, total cholesterol, HDL, LDL, triglycerides, VO2
7 69.3±2.5 0% End. 30 min 4 unclear
Sridhar 2010 India RCT 55 61.8±3.1 56% End. 12 Unclear 45 min 5 Yes HRV lying: ↗ ratio between longest RR and shortest Yes 1 HbA1c, BMI, blood pressure
50 59.5±2.8 55% Control -
Wormgoor 2018 New Zealand R Comp. Type of exercise 11 52.5±7.0 100% End. & Resist. 3 and 6 Up to 26 min 55% eWLmax & 2 sets of 12 repetitions at 75% of 1-RM 60 min 3 +/- HRV lying: ratio between longest RR and shortest Yes 1 HbA1c, BMI, HDL, triglycerides, VO2
11 52.2±7.1 100% HIIT & Resist Up to 12 (or 8) intervals of 1 min at 95% (or 120) eWLmax with 1 (or 2.25) min at 40 (or 30)% eWLmax between each & 2 sets of 12 repetitions at 75% of 1-RM +/-
Zoppini 2007 Italy Pre-post 12 65.7±5.6 42% End. 6 50–70% of HRR 60 min 2 Yes HRV lying (RR, TP, LF, HF, LF/HF) No 10 HbA1c, BMI, blood pressure, HDL, LDL, triglycerides

1-RM: one repetition maximum, DB: Deep Breathing, End.: endurance training, eWLmax: estimate maximal workload, HBP: high-blood pressure; HIIT: high intensity interval training, HRR: heart rate reserve, MHR: maximum heart rate, N: sample size, Non-RCT: non-randomized controlled trial, R Comp. Type of exercise: randomized comparative on type of exercise, RCT: randomized controlled trial, Resist.: resistance training, RPE: rating of perceived exertion, RPM: revolutions per minute, Tge: gas-exchange threshold, +/- means partially supervised, * supervised during 12 weeks, not supervised after, data at 6 months considered as “partially supervised”.

*: only significant increase (↗) or decrease (↘) are presented (differences between groups or after vs before exercise training).

†: not included in the meta-analyses.